Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study

S/V initiation was associated with sustained improvements in NT-proBNP, quality of life and cardiac remodeling. S/V discontinuation or dose reduction identified patients at higher MACE risk.